| Keratoconjunctivitis Sicca
Cequa vs Restasis
Side-by-side clinical, coverage, and cost comparison for keratoconjunctivitis sicca.Deep comparison between: Cequa vs Restasis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRestasis has a higher rate of injection site reactions vs Cequa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Restasis but not Cequa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cequa
Restasis
At A Glance
Ophthalmic
Twice daily
Calcineurin inhibitor immunosuppressant
Ophthalmic
Twice daily
Calcineurin inhibitor immunosuppressant
Indications
- Keratoconjunctivitis Sicca
- Keratoconjunctivitis Sicca
Dosing
Keratoconjunctivitis Sicca Instill one drop twice daily (approximately 12 hours apart) into each eye; allow a 15-minute interval if used concomitantly with artificial tears; discard vial immediately after use in both eyes.
Keratoconjunctivitis Sicca Instill one drop twice daily in each eye approximately 12 hours apart; may be used concomitantly with lubricant eye drops, allowing a 15-minute interval between products; discard vial immediately after use.
Contraindications
—
- Known or suspected hypersensitivity to any of the ingredients in the formulation
Adverse Reactions
Most common (>5%) Instillation site pain, conjunctival hyperemia
Other (1-5%) Blepharitis, eye irritation, headache, urinary tract infection
Most common (>=1%) Ocular burning, conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, visual disturbance
Serious Potential for eye injury and contamination
Postmarketing Hypersensitivity (eye swelling, urticaria, angioedema, face swelling, tongue swelling, pharyngeal edema, dyspnea), superficial eye injury
Pharmacology
Cyclosporine is a calcineurin inhibitor immunosuppressant; when applied topically to the eye, it is thought to act as a partial immunomodulator in patients whose tear production is suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, though the exact mechanism of action is not known.
Cyclosporine is an immunosuppressive agent when administered systemically; when applied topically as an ophthalmic emulsion, it is thought to act as a partial immunomodulator in patients whose tear production is suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, though the exact mechanism of action is not known.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cequa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Restasis
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (4/12)
UnitedHealthcare
Cequa
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Restasis
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Cequa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Restasis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cequa.
No savings programs available for Restasis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RestasisView full Restasis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.